PHASE 2 STUDY OF TELATINIB IN COMBINATION WITH CAPECITABINE AND CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED CANCER OF THE STOMACH OR GASTRO-ESOPHAGEAL JUNCTION (GEJ)

被引：0
|
作者：
Alsina, M. [1 ]
Ajani, J. A. [2 ]
Ko, A. H. [3 ]
Garcia De Paredes, M. L. [4 ]
Rivera, F. [5 ]
Schwartzberg, L. [6 ]
Phan, A. T. [2 ]
Whiteside, M. [7 ]
Kunkel, L. A. [6 ,8 ]
Tabernero, J. [9 ]
机构：
[1] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain
[2] Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol Dept, Houston, TX 77030 USA
[3] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Hematol Oncol, San Francisco, CA USA
[4] Hosp Univ Ramon y Cajal, Madrid, Spain
[5] Hosp Univ Marques de Valdecilla, Dept Med Oncol, Santander, Spain
[6] West Clin, Memphis, TN USA
[7] ACT Biotech Inc, Clin Operat, San Francisco, CA USA
[8] ACT Biotech Inc, Clin Dev, San Francisco, CA USA
[9] Vall dHebron Univ Hosp, Med Oncol Serv, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：229 / 229
页数：1
相关论文
共 50 条
  • [31] First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
    van Meerten, E.
    Eskens, F. A. L. M.
    van Gameren, E. C.
    Doorn, L.
    van der Gaast, A.
    BRITISH JOURNAL OF CANCER, 2007, 96 (09) : 1348 - 1352
  • [32] Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer
    Zeuli, M
    Nardoni, C
    Pino, MS
    Gamucci, T
    Gabriele, A
    Ferraresi, V
    Giannarelli, D
    Cognetti, F
    ANNALS OF ONCOLOGY, 2003, 14 (09) : 1378 - 1382
  • [33] Efficacy and Toxicity of Cisplatin and Capecitabine Combination in the First-Line Treatment of Patients with Advanced Gastric Cancer: A Multicenter Study by the Anatolian Society of Medical Oncology
    Ciltas, Aydin
    Buyukberber, Suleyman
    Topcu, Turkan O.
    Kucukoner, Mehmet
    Uyeturk, Ummugul
    Cihan, Sener
    Sendur, Mehmet A.
    Budakoglu, Burcin
    Kefeli, Umut
    Yildiz, Ramazan
    Goksel, Gamze
    Berk, Veli
    Balakan, Ozan
    Oksuzoglu, Berna
    Uncu, Dogan
    Coskun, Ugur
    Ozdemir, Feyyaz
    Benekli, Mustafa
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2016, 26 (02): : 96 - 102
  • [34] Current and Emerging Role of Monoclonal Antibody-Based First-Line Treatment in Advanced Gastro-Esophageal and Gastric Cancer
    Desilets, Audrey
    Elkhoury, Reem
    Gebai, Ahmad
    Tehfe, Mustapha
    CURRENT ONCOLOGY, 2023, 30 (10) : 9304 - 9316
  • [35] Modified Docetaxel and Cisplatin in Combination with Capecitabine (DCX) as a First-Line Treatment in HER2-Negative Advanced Gastric Cancer
    Bilici, Ahmet
    Selcukbiricik, Fatih
    Demir, Nazan
    Ustaalioglu, Bala Basak Oven
    Dikilitas, Mustafa
    Yildiz, Ozcan
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (20) : 8661 - 8666
  • [36] Efficacy and safety of cisplatin and capecitabine in combination as first line treatment for unselected patients with advanced gastric cancer
    Viteri, Ainhoa
    Munoz, Alberto
    Rubio, Itziar
    Barcelo, Ramon
    Martinez-Bueno, Alejandro
    Fernandez, Ricardo
    Carrera, Sergio
    Lopez-Vivanco, Guillermo
    ACTA ONCOLOGICA, 2007, 46 (03) : 397 - 399
  • [37] Modified Docetaxel-cisplatin in Combination with Capecitabine as First-line Treatment in Metastatic Gastric Cancer. A Phase II Study
    Polyzos, Aristides
    Felekouras, Evangellos
    Karatzas, Theodore
    Griniatsos, John
    Dimitroulis, Dimitrios
    Polyzos, Kostas
    Kontzoglou, Kostas
    Mantas, Dimitrios
    Karavokyros, John
    Nikiteas, Nikolaos
    Tsavaris, Nikolas
    Syrigos, Kostas
    Vafiadis, Irene
    ANTICANCER RESEARCH, 2012, 32 (09) : 4151 - 4156
  • [38] Phase I/II study of genasense (G3139) in combination with cisplatin (Cis) and fluorouracil (FU) in patients with advanced esophageal, gastro-esophageal junction and gastric cancer (P5385).
    Kaubisch, A
    Wu, YH
    Wadler, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 884S - 884S
  • [39] Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer
    Vrdoljak, Eduard
    Omrcen, Tomislav
    Boban, Marijo
    Hrabar, Andina
    ANTI-CANCER DRUGS, 2011, 22 (02) : 191 - 197
  • [40] Phase II study of capecitabine and cisplatin as first-line therapy in patients with recurrent or metastatic esophageal carcinoma.
    Lee, J
    Im, YH
    Kang, JH
    Nam, E
    Lee, SH
    Park, JO
    Park, YS
    Kang, WK
    Park, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 362S - 362S
12345